LMNX News 17.36 Luminex Cor (LMNX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Luminex Cor (LMNX) 17.36 $LMNX

Global Companion Diagnostics Market 2014-2018 with Abbott Laboratories, Agilent Technologies, bioMerieux SA, Qiagen N.V. & Roche Holding Dominating
M2 - Wed Apr 16, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3lb2g2/global_companion) has announced the addition of the "Global Companion Diagnostics Market 2014-2018" report to their offering. The Global Companion Diagnostics market will grow at a CAGR of 18.59 percent over the period 2013-2018. One of the major trends being witnessed in the market is the increase in growth strategies among vendors. Many diagnostic companies are adopting various strategies such as licensing agreements, product launches, collaborations, acquisitions, capital investment, and government support to develop companion diagnostic theranostic tests and targeted therapeutics and to strengthen their diagnostics product portfolio. Thus, many such activities are expected to boost the development of new diagnostic devices, thereby bolstering the growth of the Global Companion Diagnostics market during the forecast period. According to the report, the increased focus on cost cutting in the drug discovery and development process is one of the major drivers. The growth of genomics and proteomics has enabled the understanding of different expression stages associated with a specific disease among the human population. This has enabled many companies to develop highly specific drugs known as targeted therapeutics. It has also allowed better management of the drug development process, resulting in effective cost management. The paradigm shift in the focus to develop targeted therapeutics has enabled the development of companion diagnostic tests to monitor and administer patients with ease. Further, the report states that one of the major challenges in this market is the high cost involved in the development of companion diagnostics. The cost of developing companion diagnostics is high and adds to the overall cost of the targeted therapeutics and diagnostic tests. This report covers the present scenario and the growth prospects of the Global Companion Diagnostics market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of companion diagnostic tests and associated kits provided by the vendors. It also presents the vendor landscape and a corresponding detailed analysis of key five vendors in the Global Companion Diagnostics market. The market is highly fragmented, with the presence of many small and large vendors. It includes vendors that operate across the globe and have a substantial presence in North America and the European Union. In addition, the report discusses the major drivers that influence the growth of the Global Companion Diagnostics market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. Key Vendors - Abbott Laboratories - Agilent Technologies Inc. - bioM?rieux SA - Qiagen N.V. - Roche Holding AG Other Prominent Vendors - 20/20 Genesystems Inc. - A & G Pharmaceutical Inc. - AccuTheranostics Inc. - Alacris Theranostics GmbH - AutoGenomics Inc. - Biogenex Laboratories Inc. - Leica Biosystems GmbH - Life Technologies Inc. - Luminex Corp. - pHLOGISTIX LLC - Spartan Bioscience Inc. - TheraDiag S.A. - Theranostics Health Inc. - Ventana Medical Systems Inc. Key Market Drivers/Trends/Challenges - Increasing Focus on Reducing the Cost of Drug Discovery and Development. - High Cost Associated with the Development of Companion Diagnostics. - Increase in Growth Strategies among Vendors Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/3l..._companion

Balanced View of Luminex Corporation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 5:30PM CDT
Luminex is optimistic about the life science research market and foresees continued favorable trends with respect to demand from its clinical customers.

Luminex Has Returned 9.8% Since SmarTrend Recommendation (LMNX)
Comtex SmarTrend(R) - Mon Apr 14, 5:16PM CDT
SmarTrend identified a Downtrend for Luminex (NASDAQ:LMNX) on March 24th, 2014 at $18.40. In approximately 3 weeks, Luminex has returned 9.84% as of today's recent price of $16.59.

Global High Throughput Screening (Cell Based, Ultra High Throughput Screening (uHTS), Label Free, Bioinformatics) Market 2014-2018
M2 - Fri Apr 11, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wnx4xn/high_throughput) has announced the addition of the "High Throughput Screening (HTS) Market by Technology, Applications & by End Users - Forecast to 2018" report to their offering. The global HTS market was valued at $13,736 million in 2013 and is expected to reach $19,627 million by 2018, at a CAGR of 7.4% In recent years, the high throughput screening (HTS) market has witnessed a large number of technological advancements, which has resulted in an increase in the rate of adoption of HTS in laboratories. . The HTS market is broadly classified into five segments, namely, technologies, products, applications, end users, and geography. The technology market is sub-divided into ultra high throughput screening, cell-based assays, lab-on-a chip, label-free technology, and bioinformatics. The cell-based assays segment dominated the HTS market in 2013, followed by the lab-on-a-chip segment. The HTS products market is broadly categorized into instruments, consumables/reagents, and software and services. The consumables/reagents segment dominated this market in 2013, with a market share of around 57%. The applications market is segmented into target identification, primary screening, toxicology, stem cell biology, and others. Target identification dominated the HTS applications market in 2013, followed by the primary screening market. The HTS market by end user is broadly categorized into pharmaceutical companies, biotechnology companies, academic and government institutes, contract research organizations (CROs), and others. The pharmaceuticals segment dominated the market in 2013, with a market share of around 48%. The major factors driving the growth of the HTS market are technological innovations, open innovation models adopted by pharmaceutical companies, increasing drug discovery initiatives by academic institutions, and huge capital investments in HTS technology by organizations. Moreover, the presence of a large untapped market in emerging countries and growth in outsourcing of drug discovery services especially in China and India are the various factors that are expected to provide growth opportunities for players in this market. However, the capital intensive nature of HTS and difficulties in assay development for novel target classes are the factors curbing the growth of this market. Company Profiles - Agilent Technologies, Inc. - Aurora Biomed - Axxam Spa - Beckman Coulter, Inc. (A Subsidiary Of Danaher) - Bio-Rad Laboratories - Biofocus Dpi Ltd. - Intellicyt Corporation - Luminex Corporation - Perkinelmer, Inc. - Sigma Aldrich Corporation - Tecan Group Ltd. - Thermo Fisher Scientific, Inc. Scope of the Report Technology - Cell-Based Assay - Ultra high throughput screening (uHTS)Lab-on-a-chip - Label Free Technology - Bioinformatics Product - Instruments - Consumables/Reagents - Software and Services Application - Target Identification - Primary Screening - Toxicology - Stem Cell Biology - Others End User - Pharmaceutical - Biotechnology - Academic & Government Organizations - Contract Research Organizations - Others For more information visit http://www.researchandmarkets.com/research/wn...throughput

Global Proteomics Market (Technology, Instruments, Reagents & Services) - Global Forecast to 2018
M2 - Tue Apr 08, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2hnkrt/proteomics_market) has announced the addition of the "Proteomics Market by Technology, Instruments, Reagents & Services - Global Forecast to 2018" report to their offering. The global market was valued at an estimated $10,223.3 million in 2013. The growth of this market is mainly fuelled by the increasing need for personalized medicine, growth in pharmaceutical and biotechnology research and development (R&D) expenditure, technological advancements, and availability of government and private funding for proteomics projects.The overall market is further divided into four major geographies, namely, North America, Europe, Asia, and the Rest of the World (RoW). These regions are further analyzed at the country level. This report discusses the key market drivers, restraints, and opportunities in the global proteomics market and its sub-markets. Based on reagents type, the market is segmented into protein microarray, spectroscopy, X-ray crystallography, chromatography, electrophoresis, immunoassay, and protein fractionation kits. Furthermore, the services market is sub-divided into analytical laboratory services, and data analysis and maintenance. Analytical laboratory services are further segmented into three types, namely, protein identification, protein separation, and protein sequencing. Data analysis and maintenance is further divided into bioinformatics databases and bioinformatics tools. North America accounted for the largest share of the global market in 2013, followed by Europe, Asia-Pacific, and the Rest of the World. Developed geographies like North America and Europe are likely to grow at lower CAGRs as compared to the Asian market. The growth in the Asian market is attributed to the shift of focus of the proteomics research-related industries towards Asia and the increase in both public and private funding to boost proteomic research in the region. Scope of the Report Proteomics Instrumentation Technologies - Protein Microarray - - Biochips - - Microarray instruments - Spectroscopy - - Mass spectrometry - - NMR spectrometry - - Circular dichroism (CD) spectroscopy - X-ray Crystallography - Chromatography - - HPLC Systems - - Affinity chromatography - - Ion chromatography - Supercritical Fluid Chromatography - Electrophoresis - - Gel electrophoresis - - Capillary electrophoresis - Surface Plasmon Resonance System (SPR System) - Protein Fractionation System Proteomics Reagents - Microarray - Spectroscopy - X-ray Crystallography - Chromatography - Electrophoresis - Immunoassay - Microsphere - Protein Fractionation Kits Proteomics Services - Analytical Laboratory Services - Protein Identification - Protein Separation - Protein Sequencing - Data Analysis and Maintenance - Bioinformatics Databases - Bioinformatics Tools - Global Proteomics Market, by Application - Drug Discovery - Diagnosis Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - Proteomics Instrumentation Technology - Proteomics Reagents Market - Proteomics Services Market - Proteomics Applications Market - Geographic Analysis - Competitive Landscape - Company Profiles - Thermo Fisher Scientific Inc. - Agilent Technologies, Inc. - Bio-Rad Laboratories, Inc. - Luminex Corporation - Danaher Corporation - Ge Healthcare - Waters Corporation - Affymetrix Inc. - Perkinelmer, Inc. - Sigma-Aldrich Corp Visit http://www.researchandmarkets.com/research/2h...ics_market

Global Multiplexed Diagnostics Market (Technologies & Applications) 2013 - 2019
M2 - Tue Apr 08, 2:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m73r7s/multiplexed) has announced the addition of the "Multiplexed Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report covers the market analysis of the multiplexed diagnostics technologies namely, very high, high, medium, low density multiplexed assays & next-generation sequencing. This report contains qualitative information about oligonucleotide arrays, phage display, bacterial artificial chromosome arrays, protein arrays, bead-based arrays, antibody arrays, reverse arrays, mass spectrometry, quantitative PCR bead-based and microplate assays and next-generation sequencing. The market is also segmented on the basis of several application areas of multiplexed diagnostics, namely, infectious disease diagnosis, oncology, autoimmune diseases, cardiac conditions, allergies and others (Alzheimer's disease, diabetes, kidney toxicity and HIV). The global multiplexed diagnostics market has phenomenally increased the volume and quality of diagnostic procedures by reducing the turnaround time and analyzing multiple analytes in a single cycle and thereby resulting in rapid adoption of such techniques. The stake holders in this market include market players who provide multiplexed diagnostic assay kits, reagents, solutions and systems. The qualitative details of the market dynamics of the multiplexed diagnostics market such as drivers, restraints and opportunities that influence the current nature and future status of this field are covered under the market overview section of this report. Impact factors such as market attractiveness analysis and Porter's five forces analysis have also been provided in the market overview section of the report in order to give a thorough analysis of the overall competitive scenario in the global multiplexed diagnostics market. The market size and forecast in terms of USD million has been provided in the report for the period 2011 to 2019. This report also includes the overall market growth rate (Compounded Annual Growth Rate) of technologies, applications and geographic market for the period 2013 to 2019, considering 2012 as the base year. The global multiplexed diagnostics market is segmented as follows: Technology - Very high density multiplexed assays - - Oligonucleotide Arrays - - Phage Display - High Density Multiplexed Assays - - Bacterial Artificial Chromosome Arrays - - Protein Arrays - Medium Density Multiplexed Assays - - Bead-based Arrays - - Antibody Arrays - - Reverse Arrays - - Mass Spectroscopy - Low Density Multiplexed Arrays - - Quantitative PCR Bead-based Assays - - Microplate Assays - Next-Generation Sequencing Application - Infectious Disease Diagnosis - Oncology - Autoimmune diseases - Cardiac - Allergies - Others Key Topics Covered: - Introduction - Executive Summary - Multiplexed Diagnostics Market Overview - Global Multiplex Assays Market, by Technology - Global Multiplex Diagnostics Market, By Application - Global Multiplexed Diagnostics Market, by Geography - Recommendations - Company Profiles - Affymetrix, Inc. - Agilent Technologies, Inc. - bioMerieux, Inc. - Bio-Rad Laboratories, Inc. - Illumina, Inc. - F. Hoffman-La Roche, Ltd. - Gen-Probe, Inc. - Life Technologies Corporation - Luminex Corporation - Seegene, Inc. Visit http://www.researchandmarkets.com/research/m7...ultiplexed

Luminex Corporation First Quarter Earnings Release Scheduled for April 28, 2014
PR Newswire - Mon Apr 07, 3:05PM CDT
Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the first quarter of 2014 on Monday, April 28, 2014. A press release announcing the results is scheduled for release after the close of trading.

Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Breakthrough for Luminex's xMAP Technology - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 2:20PM CDT
Luminex's xMAP Technology will be deployed by the HPA project to perform flexible and high-throughput screening of biomarkers using the HPA antibodies on large numbers of samples.

Pioneering Human Protein Atlas Project Achieves a Major Milestone
PR Newswire - Mon Mar 17, 3:05PM CDT
Luminex Corporation (NASDAQ: LMNX) announced today that xMAP® Technology is playing a key role in the biobank profiling research within the Human Protein Atlas (HPA) project. In the latest release of the protein atlas, the HPA announced coverage of over 80% of the human protein-coding genes and RNA expression data for more than 90% of the genes.

Global Flow Cytometry (Products, Application, Technology, and Users) Market Report 2012-2020
M2 - Thu Mar 06, 11:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/hrg48g/flow_cytometry) has announced the addition of the "Flow Cytometry Market (Products, Application, Technology, and Users) - Current Trends, Opportunities, Industry Analysis, Size, Share and Global Forecast, 2012-2020" report to their offering. The flow cytometry market valued $3 billion in 2012 is further expected to reach $6.5 billion by 2020 growing at a CAGR of 30.9% Flow cytometry measures and analyzes cells of various characterizations through a light beam that is passed through a suspension of fluid. Several properties of the cell structure and functions can be studied with the help of this technique. The factor driving this market is the increase in scope of application areas such as drug discovery, stem cell sorting, marine biology, etc. The major limitation of this market is the cost of the instrument due to the need for high investment for production and maintenance. Flow cytometry finds its opportunities in the clinical and research approaches. KEY MARKET SEGMENTS BY PRODUCT - FC instruments - Reagents - Consumables - Software - Services - Accessories BY TECHNOLOGY - Cell based Technologies - Bead-based Technologies BY APPLICATION - Clinical - Apoptosis - Cell Cycle Analysis - Cell sorting - Cell Viability - Research Fields - Organ transplantation - Cancer - Immunodeficiency Disease - Hematology Haematological Malignancies BY END USERS - Commercial Organizations - Hospitals - Academic Institutes - Medical Schools - Clinical Testing Labs - Others KEY AUDIENCES: - Clinical institutes - Research institutes - Pharma and biotech companies - Academic institutes Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Flow Cytometry Market Overview Chapter 4 Flow Cytometry Market By Product Chapter 5 Flow Cytometry Market By Technology Chapter 6 Flow Cytometry Market By Application Chapter 7 Flow Cytometry Market By End User Chapter 8 Flow Cytometry Market By Geography Chapter 9 Company Profiles - Advanced Analytical Technologies Inc (AATI) - Amnis Corporation - Beckman Coulter - Becton - Dickinson & Co. - Ebioscience Inc. - Inc. - Life Technologies Corporation - Luminex Corporation - Merck Millipore - Morphosys AG - Partec GmbH For more information visit http://www.researchandmarkets.com/research/hr..._cytometry

NextGxDx Secures Series B Financing Round, Expands Board of Directors
PR Newswire - Wed Mar 05, 7:30AM CST
NextGxDx Inc., which provides an online genetic testing marketplace for healthcare professionals and hospitals, today announced the successful closing of the company's Series B round of financing, which was led by Voyent Partners and joined by the Nashville Capital Network. With the new investment, the company has expanded its board of directors to include new members Patrick J. Balthrop Sr., President and CEO of Luminex Corporation; Phil Hertik, former founder, chairman and CEO of Windsor Health Group; Jim Kever, principal at Voyent Partners; George Lazenby, former CEO of Emdeon; and G. Walter Loewenbaum II, chairman of Luminex Corp. and 3D Systems Corp.

12.6% Return Seen to Date on SmarTrend Luminex Call (LMNX)
Comtex SmarTrend(R) - Mon Mar 03, 11:05AM CST
SmarTrend identified a Downtrend for Luminex (NASDAQ:LMNX) on July 30th, 2013 at $21.00. In approximately 7 months, Luminex has returned 12.60% as of today's recent price of $18.35.

Global Gene Expression (DNA Microarray, Real-Time PCR, Next Generation Sequencing) Analysis Market 2014-2018
M2 - Thu Feb 27, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/dqf4hv/gene_expression) has announced the addition of the "Gene Expression Analysis Market by Technology, Consumables, Services & Applications - Global Forecast to 2018" report to their offering. The global market was valued at $2.6 billion in 2013 and is expected to reach $4.3 billion by 2018, at a CAGR of 10.4% Over the years, the gene expression analysis market, comprising of instruments, consumables, and services, has witnessed various technological advancements. These advancements have led to a growth in the number of gene expression applications. Some of the applications using gene expression analysis are pharmacogenomics, diagnostics, toxicogenomics, and biomarkers. However, the high cost of instruments and the need for skilled professionals to operate these highly sophisticated systems are factors that are hindering the market. The global gene expression analysis market witnesses high competitive intensity as there are many big and small firms with similar product offerings. These companies adopt various strategies (innovations, acquisitions, and geographic expansions related to endoscopy products) to increase their market shares and to establish a strong foothold in the global market. The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms in garnering a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares. Scope of the Report - Market Penetration: Comprehensive information on the product portfolios and services offered by the top 10 players in the gene expression analysis market. The report analyzes instruments (by technology), consumables, and services - Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the gene expression analysis market - Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various gene expression analysis products across geographies - Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the gene expression analysis market - Competitive Assessment: In-depth assessment of market shares, strategies, products and services, distribution networks, and manufacturing capabilities of leading players in the gene expression analysis market Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Gene Expression Analysis Market, By Segment 5 Gene Expression Analysis Instrumentation Market, By Technology 6 Gene Expression Analysis Consumables Market, By Product 7 Gene Expression Analysis Services Market, By Product 8 Gene Expression Analysis Market, By Application 9 Geographic Analysis 10 Competitive Landscape 11 Company Profiles - Affymetrix, Inc. - Agilent Technologies - Bio-Rad Laboratories, Inc. - Ge Healthcare (Subsidiary Of General Electric Company) - Illumina, Inc. - Life Technologies - Luminex Corporation - Oxford Gene Technology, Inc. - Perkinelmer, Inc. - Qiagen N.V. - Roche Diagnostics Corporation For more information visit http://www.researchandmarkets.com/research/dq...expression

Luminex Down 10.5% Since SmarTrend Downtrend Call (LMNX)
Comtex SmarTrend(R) - Fri Feb 21, 5:25PM CST
SmarTrend identified a Downtrend for Luminex (NASDAQ:LMNX) on July 30th, 2013 at $21.00. In approximately 7 months, Luminex has returned 10.45% as of today's recent price of $18.80.

High Throughput Screening - Forecast to 2018 Research Report
M2 - Tue Feb 11, 9:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/mxsthj/high_throughput) has announced the addition of the "High Throughput Screening (HTS) Market by Technology, Applications & by End Users - Forecast to 2018" report to their offering. 'High Throughput Screening (HTS) Market by Technology (Cell Based, Ultra High Throughput Screening (uHTS), Label Free, Bioinformatics), by Apllications (Target Identification, Primary Screening, Toxicology, Stem Cell) & by End Users (Pharmaceutical Industry, Biotechnology Industry, CRO) - Forecast to 2018' In this report, the global high throughput screening (HTS) market has been segmented on the basis of technology, products, applications, end users, and geography. The label-free technology market is expected to grow at the highest CAGR of 11.1% from 2013 to 2018. This technology offers the direct detection ability, which was not possible with cell-based assays. Moreover, this technology helps in the reduction of drug failure rate due to toxicity and is applicable for a majority of drug classes. In the HTS applications market, the target identification segment accounted for the largest share in 2013. The large share of this segment can be attributed to factors such as the availability of large compound libraries, presence of well-equipped HTS laboratories, and technological advancements. Large pharmaceutical and biotechnology companies are investing heavily in automation of HTS laboratories and are also entering into strategic partnerships and collaborations with research institutes, thereby leading to efficient utilization of HTS in varied application fields. Key Topics Covered: Introduction Executive Summary Premium Insights Market Overview High Throughput Screening Market, By Technology High Throughput Screening Market, By Product Global High Throughput Screening Market, By Application Global High Throughput Screening Market, By End Users Geographic Analysis Competitive Landscape Company Profiles List of Tables List of Figures Companies Mentioned - Agilent Technologies, Inc. - Aurora Biomed - Axxam Spa - Beckman Coulter, Inc. (A Subsidiary Of Danaher) - Bio-Rad Laboratories - Biofocus Dpi Ltd. - Intellicyt Corporation - Luminex Corporation - Perkinelmer, Inc. - Sigma Aldrich Corporation - Tecan Group Ltd. - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/mx...throughput About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Luminex Earnings Beat but Fall Y/Y, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 9:34AM CST
The decline in earnings can be attributable to lower revenues and higher costs during the quarter.

Luminex Corporation Reports Fourth Quarter And Full Year 2013 Results
PR Newswire - Mon Feb 03, 3:05PM CST
Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and year ended December 31, 2013. Financial and operating highlights include the following:
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 391

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 149

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
PayPal Adds a Risk Hand to Its Board at a Crucial Turn

Updated Category News Views 91

A Boardroom Hire With Some Actual Weight PayPal did not go hunting for another decorative résumé. Brian J. Lee, set to join the board on November 30, 2026, spent decades inside Goldman Sachs, including a stint as chief risk officer from 2019 through January 2025. For a payments company trying to sharpen its financial-services identity, that is a serious piece of...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Travel Awards Spotlight Luxury Hospitality's Reach

Updated Category News Views 90

Hong Kong’s awards roll call reads less like a scorecard than a map of where premium travel wants its money and attention to go next. The 2026 World’s Travel & Hotel Awards, released November 20, cast a very wide net: heritage palaces, city hotels, beach retreats, airlines, cruise operators, tourism boards, restaurants, serviced apartments and a fair number of...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 41

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 73

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Union Pacific Faces $98.8 Million Arbitration Tab

Updated Category News Views 109

A Missed Schedule Promise Got Very Expensive Railroad labor disputes can look like paperwork until the bill lands with a thud. Union Pacific is facing an estimated $98.8 million arbitration payout after a Special Board of Adjustments found that the carrier failed to implement a negotiated scheduling benefit for locomotive engineers. That is not loose change, and it is the...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 60

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 87

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Physician Compensation Management at Southwell

Updated Category News Views 112

Revolutionizing Physician Compensation with Clinician Nexus In a significant move towards streamlining physician compensation processes, Southwell, a notable health system in South Central Georgia, has partnered with Clinician Nexus, a leader in clinical workforce technology. This collaboration will introduce Clinician Nexus’ advanced physician compensation management...

Continue Reading
Transforming a $1000 Investment in Digital Realty Trust Today

Updated Category News Views 208

Long-Term Investing Success with Digital Realty Trust Digital Realty Trust (NYSE: DLR) has shown remarkable performance in the financial markets, surpassing typical market returns consistently over the last two decades. With an impressive annualized return of 11.8%, this company has proven its capability to deliver value to its investors. The Growth of Your Initial...

Continue Reading
Investigation Launched on Markforged Shareholder Deal Fairness

Updated Category News Views 89

So here’s the scoop: Ademi LLP has kicked off an investigation into Markforged Holding Corporation (NYSE: MKFG), and it’s not just for show. The focus? To unpack whether the company’s board is doing their job right in a deal that smells a bit fishy with Nano Dimension. A Stinky Deal Under this agreement, shareholders are looking at a measly $5.00 per share—sounds...

Continue Reading
Introducing Noel Ortega: A Transformative Leader at SAFCO

Updated Category News Views 179

SAFCO Welcomes New Leadership in Account Services Southern Auto Finance Company, LLC (SAFCO) is thrilled to announce that Noel Ortega has been appointed as the new Senior Vice President of Account Services. Mr. Ortega comes with a wealth of knowledge from over 20 years in the auto finance sector, emphasizing collections and outstanding customer service. Mr. Ortega's...

Continue Reading
BBG Expands Services with New Data Center Specialty Practice

Updated Category News Views 167

BBG Unveils New Data Center Specialty Practice BBG, a prominent figure in the national commercial real estate services arena, has recently launched a dedicated Data Center Specialty Practice to address the surging demand for valuation and advisory services within the mission-critical infrastructure domain. Leading the charge is Christopher M. Fudacz, a seasoned expert in...

Continue Reading